GlassScriptPhysician profile
Gustavo Cadavid
NPI 1518256957
$10,318.43
in general payments reported to CMS, 2019-2025
69 companies · $1,788 in 2025
The $1,788 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $953 · 2021: $1,578 · 2022: $1,994 · 2023: $1,440 · 2024: $1,929 · 2025: $1,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,114 · Education: $43.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,114.16 |
| Education | $43.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $937.57 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $861.02 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $749.88 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $730.60 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $727.66 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pfizer INC. | $559.18 | 2019-2024 | |
| Daiichi Sankyo INC. | $465.55 | 2020-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $392.22 | 2019-2025 | Krazati, Opdivo |
| Celgene Corporation | $342.16 | 2019-2024 | Pomalyst, Reblozyl |
| Incyte Corporation | $312.60 | 2019-2023 | Jakafi |
| Amgen INC. | $234.40 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $225.03 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Genzyme Corporation | $211.97 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $183.43 | 2019-2025 | Libtayo |
| Lilly USA, LLC | $180.02 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Cadavid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.